Capricor Therapeutics, Inc. CAPR
8.30 USD 0.00 (+0.00%)
Regular-session close
8.78 +0.48 +5.78%
Pre-market · Nov 17, 9:03 AM ET
Day range unavailable
2.96 52-week range 40.37
- YTD
- -71.24%
- 1 year
- +48.21%
News
benzinga.com Biotech ETFs Brace for FDA Showdown: Two Drug Decisions Could Test Investor Sentiment XBI and IBB lagged SPY and QQQ as two FDA decisions and fresh Alzheimer's and obesity-drug data put biotech ETFs in focus.benzinga.com Roth Capital Reiterates Neutral on Capricor Therapeutics, Raises Price Target to $10.5 Roth Capital analyst Boobalan Pachaiyappan reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Neutral and raises the price target from $7 to $10.5.
benzinga.com Jones Trading Upgrades Capricor Therapeutics to Buy, Announces $25 Price Target Jones Trading analyst Catherine Novack upgrades Capricor Therapeutics (NASDAQ:CAPR) from Hold to Buy and announces $25 price target.
benzinga.com Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are trading higher Wednesday despite the company missing earnings per share estimates in its third-quarter results Tuesday after the market closed.
benzinga.com Capricor Stock Rises Despite Wider-Than-Expected Q3 Loss Capricor Therapeutics shares are trading higher Wednesday despite a wider-than-expected Q3 loss Tuesday after the market closed.
seekingalpha.com Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
marketbeat.com Capricor Therapeutics Q3 Earnings Call Highlights Capricor Therapeutics NASDAQ: CAPR is awaiting a Nov. 22 Food and Drug Administration decision on Deramiocel for Duchenne muscular dystrophy, as the company prepares for a potential launch while…
benzinga.com Capricor Therapeutics Q3 2026 Earnings Call Transcript Capricor Therapeutics (NASDAQ:CAPR) held its third-quarter earnings conference call on Tuesday. Below is the complete transcript from the call.This transcript is brought to you by Benzinga APIs. For…benzinga.com Capricor Therapeutics Q3 EPS $(0.73) Misses $(0.05) Estimate Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.05) by 1360 percent. This is a 35.19 percent decrease over losses…
globenewswire.com Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update SAN DIEGO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare…
benzinga.com Why Inovio Pharmaceuticals Shares Are Trading Higher By Over 230%; Here Are 20 Stocks Moving Premarket Inovio shares surged 230% premarket after FDA accelerated Voceryq approval; ClearOne and 22nd Century gained, while RedCloud fell 33.5%.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…
